Cell Replacement Strategies Aimed at Reconstitution of the β-Cell Compartment in Type 1 Diabetes | Zendy

Giuseppe Orlando | Zendy; Pierre Gianello | Zendy; Marcus Salvatori | Zendy; Robert J. Stratta | Zendy; Shay Söker | Zendy; Camillo Ricordi | Zendy; Juan DomínguezBendala | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cell Replacement Strategies Aimed at Reconstitution of the β-Cell Compartment in Type 1 Diabetes

Author(s) -

Giuseppe Orlando,

Pierre Gianello,

Marcus Salvatori,

Robert J. Stratta,

Shay Söker,

Camillo Ricordi,

Juan DomínguezBendala

Publication year - 2014

Publication title -

diabetes

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.219

H-Index - 330

eISSN - 1939-327X

pISSN - 0012-1797

DOI - 10.2337/db13-1742

Subject(s) - regenerative medicine , pancreas , reprogramming , compartment (ship) , diabetes mellitus , stem cell , repopulation , endocrine system , immune system , islet , medicine , biology , microbiology and biotechnology , cell , regeneration (biology) , immunology , bioinformatics , endocrinology , hormone , haematopoiesis , oceanography , genetics , geology

Emerging technologies in regenerative medicine have the potential to restore the β-cell compartment in diabetic patients, thereby overcoming the inadequacies of current treatment strategies and organ supply. Novel approaches include: 1) Encapsulation technology that protects islet transplants from host immune surveillance; 2) stem cell therapies and cellular reprogramming, which seek to regenerate the depleted β-cell compartment; and 3) whole-organ bioengineering, which capitalizes on the innate properties of the pancreas extracellular matrix to drive cellular repopulation. Collaborative efforts across these subfields of regenerative medicine seek to ultimately produce a bioengineered pancreas capable of restoring endocrine function in patients with insulin-dependent diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research